The PTAB’s decision invalidates all claims of the patent that were directed to a method for treating rheumatoid arthritis by administering 40 mg of HUMIRA subcutaneously every 13 to 15 days.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”